News Sentiment

GERN sentiment intelligence

Geron Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.50 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+10.3% over one week, +30.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Geron (GERN) Is Signaling Commercial Ambition, Not Just Handing Out Options

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 10.3% Price confirming higher
Trend fit Trend inactive 30.4% over four weeks
Fair value -37.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 35
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
Stock Titan 8
simplywall.st 7
TradingView 3
Seeking Alpha 3
TradingKey 3
Investing.com 2
StocksToTrade 2

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 20
Analyst action 2
Deals and strategy 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Market source Direct company coverage

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation announced an inducement grant in the form of a stock option to purchase 1,700,000 shares of its common stock for Chinmaya Rath, the new Chief Business Officer. The grant, made on July 13, 2026, has an exercise price of $1.42 per share and vests over four years,

Tone
Positive 59/100
Event
Market update
Published
14 Jul 2026 20:26
Source
Market source
Stock Titan Direct company coverage

Geron's New Business Chief Gets Option on 1.7M Shares

Geron (GERN) granted a stock option to its new Chief Business Officer, Chinmaya Rath, entitling him to purchase 1.7 million shares of common stock. This inducement award, detailed in a recent report, has an exercise price of $1.42 per share, matching the closing price on the gran

Tone
Positive 62/100
Event
Market update
Published
14 Jul 2026 20:17
Source
Stock Titan
Stock Titan Direct company coverage

Veteran dealmaker from Novartis and Cellworks joins Geron to steer RYTELO growth

Geron (Nasdaq: GERN) has appointed Chinmaya Rath as its new Chief Business Officer, effective July 13, 2026. Rath brings over 25 years of biopharma leadership experience from companies like Novartis and Cellworks, and will focus on maximizing RYTELO's global value and expanding G

Tone
Positive 74/100
Event
Market update
Published
13 Jul 2026 17:12
Source
Stock Titan
Investing.com Direct company coverage

Geron appoints Chinmaya Rath as chief business officer

Geron Corporation has appointed Chinmaya Rath as Chief Business Officer, leveraging his 25 years of biopharmaceutical leadership experience from companies like Novartis and Cellworks. Rath will contribute to the commercial-stage company, which markets RYTELO for myelodysplastic s

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 13:09
Source
Investing.com
Yahoo! Finance Canada Direct company coverage

Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

Geron Corporation has appointed Chinmaya Rath as its new Chief Business Officer. Rath brings over 25 years of biopharmaceutical leadership experience and will focus on maximizing the value of Geron's drug RYTELO and exploring new opportunities to expand the company's hematology p

Tone
Positive 74/100
Event
Market update
Published
13 Jul 2026 12:09
Source
Yahoo! Finance Canada
TradingView Direct company coverage

ETFs Investing in Geron Corporation Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold shares of Geron Corporation (0IV3 on the London Stock Exchange). It details various ETFs, including their market value, weight of Geron stock, issuer, management style, expense ratio, assets unde

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 00:40
Source
TradingView
Ad-hoc-news.de Direct company coverage

Geron stock leans on its myelofibrosis story

Geron's stock performance is closely linked to the commercial rollout of its lead product, Rytelo, for myelofibrosis. The biotechnology company, listed on Nasdaq, focuses on blood-cancer therapies, with execution in sales adoption and physician uptake being crucial for its market

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 12:43
Source
Ad-hoc-news.de
Stock Titan Direct company coverage

Geron (GERN) director Robert J. Spiegel receives 6,103-share stock grant for board fees

Geron Corp. (GERN) director Robert J. Spiegel received a grant of 6,103 shares of common stock on June 30, 2026, as compensation for his quarterly board retainer and committee fees. The shares were valued at $1.28 each, based on the closing price of the company's stock that day.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:40
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Geron Corporation For: 1 July By Investing.com

This article from Investing.com announces the filing of a Form 4 for Geron Corporation on July 1st. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders (officers, directors, or beneficial owners of more than 10% of a

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:40
Source
Investing.com Canada
TradingView Direct company coverage

GERN Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Geron Corporation (GERN) stock, indicating current stock performance, analyst opinions, and key financial metrics. It highlights GERN's present stock price, recent percentage changes, historical highs and lows, and upcoming ea

Tone
Positive 61/100
Event
Analyst action
Published
25 Jun 2026 22:10
Source
TradingView
StocksToTrade Direct company coverage

GERN Stock Steadies As Geron Builds Commercial Momentum

Geron Corporation (GERN) stock is experiencing a 7.14% increase due to positive sentiment surrounding its late-stage blood cancer therapy. The company has granted significant stock options to new employees, signaling aggressive talent acquisition, and is demonstrating commercial

Tone
Positive 69/100
Event
Deals and strategy
Published
22 Jun 2026 17:40
Source
StocksToTrade
The Manila Times Direct company coverage

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation announced inducement grants of stock options to eight new employees, as specified under Nasdaq Listing Rule 5635(c)(4). These grants, totaling 690,000 shares, have an exercise price of $1.23 per share and a ten-year term, vesting over four years. Geron is a comm

Tone
Positive 63/100
Event
Market update
Published
20 Jun 2026 10:39
Source
The Manila Times
Stock Titan Direct company coverage

Geron dangles 690,000 options to recruit eight new employees

Geron (Nasdaq: GERN) granted 690,000 stock options to eight new employees as inducement awards on June 17, 2026. The options have an exercise price of $1.23 per share, matching the closing price on the grant date, and vest over four years. This move resulted in a 6.35% increase i

Tone
Positive 74/100
Event
Market update
Published
18 Jun 2026 15:40
Source
Stock Titan
TradingKey Direct company coverage

Geron Corp (GERN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Geron Corp (GERN), listing major institutional shareholders like RA Capital Management and BlackRock. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent changes in shareholdings

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 15:13
Source
TradingKey
TradingKey Direct company coverage

Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article "Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution" from TradingKey states that relevant revenue data by business segment and region has not been disclosed by the company yet. It provides current stock information for Geron

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 11:09
Source
TradingKey
TradingKey Direct company coverage

Geron Corp (GERN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Geron Corp (GERN) stock, focusing on its historical dividends and stock splits. It indicates that Geron Corp has not distributed any dividends over the past five years and there is no data available for historical stock splits. The piece prese

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 10:09
Source
TradingKey
Quartr Direct company coverage

Geron (GERN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary

This article summarizes Geron's presentation at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026, highlighting the company's transition to a commercial stage with its drug RYTELO. RYTELO, approved for lower-risk MDS, is seeing increasing uptake and is positioned

Tone
Positive 93/100
Event
Market update
Published
12 Jun 2026 19:39
Source
Quartr
StocksToTrade Direct company coverage

GERN Stock Builds Momentum On Strong RYTELO Data

Geron Corporation (GERN) stock is gaining momentum, trading up 10.36% due to positive real-world data for its drug RYTELO in lower-risk myelodysplastic syndromes (MDS). The data shows a 37.5% red blood cell transfusion independence rate, consistent with Phase 3 trials and suggest

Tone
Positive 74/100
Event
Market update
Published
12 Jun 2026 17:09
Source
StocksToTrade
AD HOC NEWS Direct company coverage

Geron Corp stock (US3741631036): Phase 3 data keeps focus on first commercial launch

Geron Corp has transitioned into a commercial-stage biotech after receiving FDA approval for its blood cancer drug imetelstat to treat lower-risk myelodysplastic syndromes (MDS) following positive Phase 3 data. The company's focus is now on the commercial launch, including pricin

Tone
Positive 71/100
Event
Regulatory and legal
Published
09 Jun 2026 18:39
Source
AD HOC NEWS
Stocktwits Direct company coverage

Why Did GERN Stock Tumble 10% Pre-Market Today?

Geron's stock (GERN) tumbled over 10% pre-market after its fourth-quarter and full-year 2025 results showed total revenue and loss per share falling below analysts' estimates. Despite this, net product sales for its blood cancer therapy RYTELO reached $48 million in Q4, with sale

Tone
Negative 31/100
Event
Earnings
Published
06 Jun 2026 14:39
Source
Stocktwits
AD HOC NEWS Direct company coverage

Geron Corp stock (US3741631036): Focus on valuation as short interest eases

Geron Corp shares are trading around the USD 1 mark on Nasdaq, with investors weighing recent pullbacks, short interest data, and valuation metrics. As of mid-May 2026, short interest saw a 7.3% decline, indicating a slight easing of bearish sentiment. Given Geron is a developmen

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 12:39
Source
AD HOC NEWS
Finviz Direct company coverage

GERN - Geron Corp Stock Price and Quote

This article provides comprehensive stock information for Geron Corp (GERN), including its latest stock price, financial overview, key statistics, and a history of analyst ratings. It also lists recent news and press releases related to the company's financial results, corporate

Tone
Neutral 50/100
Event
Earnings
Published
04 Jun 2026 14:09
Source
Finviz
Stock Titan Direct company coverage

GERN SEC Filings - Geron Corp 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Geron Corp (GERN) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-generated summaries and sentiment analysis. Key filings include the appointment of Harout Semerjian as the new CEO with details on his compensation and equi

Tone
Positive 63/100
Event
Market update
Published
03 Jun 2026 19:09
Source
Stock Titan